Patient Profile 2: Managing ICANS Following CAR T-Cell Therapy
Donna Catamero, ANP-BC, OCN, CCRC, presents the case of a 77-year-old patient who experienced ICANS following CAR T-cell therapy and describes the role of the ICE score.
EP: 1.Unique Challenges in Managing Adverse Events Associated with CAR T-Cell Therapy
EP: 2.Navigating CAR T-Cell Therapy in Multiple Myeloma: A Collaborative, Patient-Centered Approach
EP: 3.Patient Profile 1: Managing CRS Following CAR T-Cell Therapy
EP: 4.Underlying Mechanisms and Signs of CRS
EP: 5.Strategies to Manage or Mitigate CRS
Now Viewing
EP: 6.Patient Profile 2: Managing ICANS Following CAR T-Cell Therapy
EP: 7.Clinical Practices for Treating ICANS Following CAR T-Cell Therapy
EP: 8.The Importance of Multidisciplinary Collaboration in CRS Management
EP: 9.Supportive Care Strategies for CAR T-Cell Therapy Recipients
EP: 10.Managing Cytopenias and HLH/MAS Following CAR T-Cell Therapy
EP: 11.Unmet Needs and Future Perspectives for CAR T-Cell Therapy in R/R MM
In this episode, Donna Catamero, ANP-BC, OCN, CCRC, presents the case of a 77-year-old patient who experienced ICANS following CAR T-cell therapy and describes the role of the ICE score.
Recent Videos
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
Related Content
![We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fa0c5316b5733cfe8ccceb396476faf0cea2f2e46-320x410.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.")
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025Podcast
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
